Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer	Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, adenoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cholangiocarcinoma, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, malignant mesothelioma, mesothelial neoplasm, mesothelioma, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, pleural neoplasm, respiratory system disorder, respiratory tract neoplasm	Active, not recruiting	Phase 1 / Phase 2	2025-08-27		NCT03907852

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Bristol-Myers Squibb	422
TCR2 Therapeutics	1

11 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Columbia University Medical center	New York	United States	224
Duke University	Durham	United States	91
Memorial Sloan Kettering Cancer Center	New York	United States	1000
National Cancer Institute	Bethesda	United States	3
Princess Margaret Cancer Centre	Toronto	Canada	10
Scri Oncology Partners	Nashville	United States	156
University of California, San Francisco	San Francisco	United States	294
University of Chicago Medical Center	Chicago	United States	152
University of Miami Sylvester Cancer Center	Miami	United States	9
University of Pennsylvania	Philadelphia	United States	507
University of Texas MD Anderson Cancer Center	Houston	United States	192